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Human mesenchymal stem cells (hMSC) have immunomodulative properties and, associated with cal-
cium phosphate (CaP) ceramics, induce bone tissue repair. However, the mechanisms of osteoinduction
by hMSC with CaP are not clearly established, in particular the role of osteoclasts and macrophages.
Biphasic calcium phosphate (BCP) particles were implanted with or without hMSC in the paratibial
muscles of nude mice. hMSC increased osteoblastic gene expression at 1 week, the presence of macro-
phages at 2 and 4 weeks, osteoclastogenesis at 4 and 8 weeks, and osteogenesis at 4 and 8 weeks. hMSC
disappeared from the implantation site after 2 weeks, indicating that hMSC were inducers rather than
effectors of bone formation. Induced blockage of osteoclastogenesis by anti-Rankl treatment signiﬁcantly
impaired bone formation, revealing the pivotal role of osteoclasts in bone formation. In summary, hMSC
positively inﬂuence the body foreign reaction by attracting circulating haematopoietic stem cells and
inducing their differentiation into macrophages M1 and osteoclasts, thus favouring bone formation.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Autologous bone grafts are considered the gold standard in bone
regeneration because of their osteogenicity, osteoinductivity,
osteoconduction and osteointegration characteristics [1]. However,
the bone harvesting procedure requires a second surgical site, at
which complications have been reported, and the quantity of bone
available for grafting is limited.
Synthetic bone substitutes, particularly calcium phosphate
(CaP) ceramics, have been proven safe and biocompatible and are
widely used to ﬁll bone defects in clinical indications such as
dental, maxillofacial and orthopaedic augmentation [2,3]. Despite
having a similar chemical composition to bone mineral [1] and
possessing osteoconductive properties, CaP ceramics lack they of Medicine, Nantes, France.
lle).
Ltd. This is an open access article uosteogenicity needed to support bone healing in critical size defects
[4] thus limiting their clinical use to small bone defects where
osteoconduction is sufﬁcient. The use of bone marrow derived
mesenchymal stem cells (MSC) in unison with synthetic biomate-
rial scaffolds may overcome the challenges of autologous bone
grafting for the regeneration of large defects. Human MSC (hMSC)
are easily isolated, expanded in culture and have the ability to
differentiate into multiple lineages such as osteoblasts, chon-
drocytes and adipocytes [5]. In vitro, hMSC cultured on CaP differ-
entiated into osteoblasts even without osteogenic supplements [6]
and in vivo bone formation is achieved by the use of MSC with
ceramic scaffolds in ectopic sites [7] and critical sized defects [8]. In
addition to their regenerative properties, MSC are also known to
have unique immunoregulatory properties [8,9]. It has been
demonstrated that transplanted hMSC promote wound healing by
recruitment of host MSC to the wound site [10] and Song and col-
leagues elegantly showed the homing of bone marrow MSC to
ectopic sites for bone formation by using a sex-mismatched dog
model [11].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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a biomaterial such as CaP due to the host response to a foreign
body. During the innate inﬂammatory reaction, monocytes which
circulate in the blood become tissue macrophages [12]. There is
evidence that MSC can regulate the macrophage M1/M2 balance to
the M2, IL-10 producing anti-inﬂammatory phenotype [13], by
secreting some M2 inducers such as interleukine-4 (IL-4), IL-13
[13], IL-6 [14], and prostaglandin E2 [15]. Bone is essential for a
functioning immune system since immune cells originate in the
bone marrow; however the signiﬁcance of immune cells to bone
tissue formation is less understood. Nonetheless, disordered bone
formation occurs in autoimmune diseases and recently it was
shown that ablation of macrophages inhibits intramembranous
bone healing [16]. The contribution of macrophages to tissue
engineered bone formation is unclear however.
While osteoclast activity is generally associated with bone
resorption, it has been demonstrated in vitro that osteoclasts
secrete mediators which induce the migration and osteogenic dif-
ferentiation of MSC [17]. In addition, the Wnt/BMP signalling
pathway and sphingosine-1-phosphate cytokines, secreted by os-
teoclasts, seem to be implicated in osteoblast precursor recruit-
ment [18]. Furthermore, osteoclast ablation was found to inhibit
ectopic bone formation by b-TCP [19]. However, the inﬂuence of
transplanted MSC on osteoclast activity during in vivo bone for-
mation is unknown.
In this study, the hypothesis that transplanted hMSC, associated
with BCP granules, can mobilize circulating monocytes thereby
favouring bone formation is tested. Speciﬁcally, we investigated the
interactions of transplanted hMSC, macrophages and osteoclasts in
ectopic ossiﬁcation in nude mice. To further elucidate the contri-
bution of osteoclasts to bone formation, we used an anti-mouse
RANKL antibody depleting osteoclast in mice [20].
2. Materials and methods
2.1. Biomaterials
Micro-porous biphasic calcium phosphate (BCP) granules of 0.5e1 mm in size
and composed of HA/b-TCP in a ratio of 20/80 inweight were used as received by the
supplier (MBCPþ®, Biomatlante, Vigneux de Bretagne, France). Brieﬂy, BCP granules
were prepared by mixing calcium deﬁcient apatite with organic pore makers, fol-
lowed by compaction and sintering at 1050 C. The overall porosity (% vol) was
75 ± 5%, with a pore size distribution of 70% (0e10 mm), 20% (10e100 mm) and 10%
(100e300 mm). Aliquots of 40 mg of BCP granules were prepared in Eppendorf
centrifuge tubes sterilized by autoclaving at 121 C for 20 min.
2.2. hMSC isolation and culture
The human bonemarrowmesenchymal stem cells (hMSC) were kindly provided
by Prof. Markus Rojewski, Institute for Clinical TransfusionMedicine, Ulm, Germany.
After receiving informed consent from adult donors, a bone marrow aspiration was
performed under local anaesthesia by haematologists. The cells were seeded at low
density on treated culture polystyrene ﬂasks (Corning) and cultured in a-modiﬁed
Eagle's medium (aMEM, LONZA), supplemented with 10% foetal bovine serum (FBS,
Lonza), 100 UI/ml penicillin, 100 mg/ml streptomycin. hMSC were isolated by plastic
adherence, ampliﬁed in culture until passage 4 in a humidiﬁed atmosphere at 37 C
and 5% CO2. hMSC were characterized by ﬂow cytometry as being positive for CD73,
CD90, CD105 and negative for CD45. Multipotency was demonstrated by culturing
cells in adipogenic, chondrocytic and osteogenic conditions, as previously described
[21]. For the preparation of cell-loaded implants, 1.4106 viable hMSC suspended in
70 mL PBS were added to 40 mg sterile BCP particles. The average time between cell
seeding and surgery was approximately 1 h.
2.3. In vivo experimental design
All animal handling and surgical procedures were conducted according to Eu-
ropean Community Guidelines (2010/63/EU) for the care and use of laboratory an-
imals. An animal experimentation protocol was prepared, submitted and approved
by the local Ethic Committee (CEEA.2012.27).
In order to evaluate the inﬂuence of transplanted hMSC on bone formation,
Adult nude NMRI Nu/Nu female mice (4 weeks old, body weight 20 g) were pur-
chased from a professional stock breeder (Janvier Labs, France). The nude mice were
kept in Hepa ﬁltered closets with water and food ad libitum and were quarantined
for a minimum of 10 days prior to surgery. The mice were randomly and equallydivided into 2 groups: BCP particles alone (40 mg) and BCP þ hMSC (40 mg and
1.4106 viable cells) that were bilaterally implanted in paratibial muscles. Fivemice
from each treatment group (n¼ 5) were followed for 1, 2, 4 or 8 weeks after surgery.
Animals were placed under general anaesthesia by inhalation of isoﬂurane (2.5%
Flucka, 1 L/min) and an intramuscular injection of the analgesic Buprenorphine
(Buprecare 60 mL/kg, Axience) was performed 30 min before surgery. A skin incision
of 0.5 cmwas made for exposing the muscle, and ﬁbres were taken away to create a
pocket where BCP granules were inserted. Skin incisions were closed with sutures
(Filapeau 4/0, Peters). The mice were euthanized under general anaesthesia by
cervical dislocation.
To determine the impact of osteoclastogenesis on bone formation initiated by
hMSC, 8 weeks experiments were reproduced in nudemicewhich received injections
ofmAb anti-RANKL. RANKL is a key factor for osteoclast differentiation and activation.
Anti-RANKL is known to drastically inhibit the formation of TRAP positive multinu-
cleated cells in vitro and in vivo [20]. Adult nude NMRI Nu/Nu femalemice (n¼ 4) were
implanted with BCP alone (40 mg on left leg) and BCP þ hMSC (40 mg and 1.4  106
viable cells, on right leg) and treated with a subcutaneous injection (50 mg dose) of
antibody anti-mouse RANKL, kindly provided by Prof. Hideo Yagita, Department of
Immunology, Juntendo University School of Medicine, Tokyo, three days before im-
plantation. This same injection regime was repeated twice a week and animals were
sacriﬁced after 8 weeks under general anaesthesia by cervical dislocation. Implants
were sectioned after euthanasia to perform histology and RNA extraction.
2.4. Histological analysis
The muscles were excised, ﬁxed in 4% paraformaldehyde, decalciﬁed in a PBS so-
lution with 0.5% paraformaldehyde 4.13% EDTA in a microwave decalcifying automat
(KOS Histostation) at 46 C. Samples were then embedded in parafﬁn and 3 mm thick
sections were cut. Three sections through each implant were attained for histological
analysis. The sections were stained with Masson's Trichrome and qualitative/quanti-
tative histological evaluations of soft-tissue in-growth and bone formationwere per-
formed. Masson's trichrome technique combines hematoxylin for cell nuclei (blue/
black), fuchsine for cytoplasm, muscle and erythrocytes (red) and light green solution
for collagen (green). Thequantity of newbonewasmeasured in separate sectionswith
the software ImageJ. The bone formationwas evaluated according to:
Newly formed bone ¼ (bone surface) * 100/[(total implant surface)  (BCP granules
surface)]
Tartrate resistant acide phosphatase (TRAP) is highly expressed by osteoclasts
and therefore can be used to stain these cells in histological sections. The sections
were stained using a commercial TRAP staining kit (Acid Phosphatase Leukocyte
Staining Kit, Sigma) following the manufacturer's instructions. Brieﬂy, the staining
solution was prepared with Fast Red TR salt (3.9 mM), naphthol AS-TR phosphate
disodium salt (2.3 mM), NeN dimethylformamide (68 mM), and L(þ)-tartaric acid
(100 mM) all diluted in sodium acetate buffer (0.1 M, pH 5.2). Deparafﬁnised sections
were incubated in the solution for 90 min at 37 C and then counterstained with
Mayer's hematoxylin. TRAP-positive stained cells appeared red. Qualitative/quan-
titative histological evaluations of osteoclasts were then performed.
2.5. In situ hybridization
In situ hybridization using the human-speciﬁc repetitive Alu sequence, which
comprises approximately 5% of the total human genome was performed for iden-
tiﬁcation of human cells. Sections were deparafﬁnized and rehydrated in graded
series of ethanol and washed with tris buffered saline (TBS) tween 0.05% pH 7.6
three times for 5 min each under gently agitation. Slides were treated with 3% H2O2
for 15 min at room temperature (RT) to block endogenous peroxidase activity, fol-
lowed by three washes with TBS tween 0.05%. Sections were then treated with
10 mg/mL proteinase K (P2308, Sigma Aldrich, France) for 10 min at 37 C. After a
further three washes for 5 min each in TBS tween 0.05%, sections were treated with
0.25% acetic acid in 0.1 M triethanolamine (TEA) pH 8.0 for 20 min at RT under
agitation. Pre-hybridization was performed for 3 h at 56 C in a hybridization buffer
containing 4  SSC (S6639, Sigma Aldrich France), 50% deionized formamide,
1 Denhardt's solution, 5% dextran sulphate and 100 mg/mL salmon sperm DNA and
molecular grade H2O. Hybridization buffer was replaced by fresh hybridization
buffer containing 70 nM DIG-labeled human locked nucleic acid (LNA) Alu probe
5DigN/50-TCTCGATCTCCTGACCTCATGA-30/3DigN (Exiqon, Vedbaek, Denmark) and
then target DNA and the probewere denatured for 5 min at 95 C. Hybridizationwas
carried out for 40 h at 56 C in a wet chamber. Sections were washed twice in
2  SSC, then twice in 0.5  SSC at 56 C for 10 min each time, followed by three
washes in TBS tween 0.05%. Finally, the hybridized probe was detected by immu-
nohistochemistry using biotin-SP-conjugated IgG fraction monoclonal mouse anti-
digoxin (Jackson Immunoresearch, Baltimore, USA) diluted 1/200 in PBS for
45 min at 37 C. After three washes in TBS tween 0.05% at RT, streptaperoxidase was
added (1/200 in TBS tween 0.05%) for 45 min at 37 C before diaminobenzidine
(DAB) substrate addition (Dako). Sections were counterstained with Gill-2 hema-
toxylin (Thermo Shandon Ltd, Runcorn, UK) dehydrated and mounted using Pertex
(HistoLab Products AB, Sweden).
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Immunohistochemistry was performed on deparafﬁnised and rehydrated sec-
tions with speciﬁc primary antibodies: CD146 antibody (ab75769, rabbit anti-
mouse, 1/200, Abcam), F4/80 antibody (MCA4976, rat anti-mouse, 1/200, Serotec),
iNOS antibody (ab15323, rabbit anti-mouse, 1/100, Abcam), CD206 antibody
(ab64693, rabbit anti-mouse, 1/1000, Abcam), CD68 (MCA1815T, mouse anti-
human, 1/100, Abd Serotex). All sections were counterstained using Gill's hema-
toxylin and mounted using permanent mounting medium. Tissue staining was
viewed using Nanozoomer 2.0 Hamamatsu slide scanner.
The CD146 antibody was used to detect pericytes in the histological sections.
CD146, also known as Mel-CAM, MUC18, A32 antigen and S-Endo1, is a membrane
glycoproteinobserved inpericyte that surround the endothelial layers [22]. The F4/80
antibodywasused todetectmacrophagesM0. The antigen, F4/80, iswell expressed in
macrophages M0 in most tissues of the developing and adult mouse. The iNOS
antibody was utilised in this study for the detection of macrophages M1. Inducible
nitric oxide synthase (iNOS) is a enzymecatalysing theproductionof nitric oxide (NO)
from L-arginine [23]. The presence of macrophages M2 was detected by the CD206
antibody. CD206, widely known as themannose receptor (MR) ormore precisely MR
C type 1 (MRC1) is a type 1 transmenbrane protein involved in innate immunity [24].
The CD68 antibody was used to detect macrophages M0. CD68 is a member of the
lysosome-associatedmembrane protein (LAMP)-1 family [25]. It is a transmembrane
glycoprotein highly expressed by monocytes and tissue macrophages [26].
2.7. Quantitative real-time reverse transcription-polymerase chain reaction (RT-
PCR)
Implants were sectioned after euthanasia to perform histology and RNA
extraction. Thus, each half of implants were transferred into a 1 mL tube with and
vigorously shaken to lyse the cells. Phase separation was performed using chloro-
form. RNA was recovered from the aqueous phase using isopropanol, and this was
followed by alcohol precipitation steps. RNA samples (4 mg) were reverse transcribed
with Maxima H Minus First Strand cDNA Synthesis Kit (Thermo Scientiﬁc) and
random primers in a total volume of 20 mL. Quantitative real-time PCR was per-
formed in the CFX96 (Bio-Rad Laboratories) with SYBR Green detection according
the manufacturer's recommendations. PCR ampliﬁcations involved 39 cycles of 30 s
at 98 C,15 s at 95 C and 30 s at 60 C. Expression of the target genewas normalized
to that of the endogenous control ribosomal protein L19. The 2eDCt (Ct: cycle
threshold) method was used to calculate the relative expression levels. Gene name
symbols with corresponding full names and the list of corresponding primer se-
quences are indicated in Table 1. The primer sequence used were speciﬁc to mouse
genome to only evaluate the host cells behaviour.
Relative gene expression for osteoblastic markers, as alkaline phosphatase (Alp),
Bone sialo protein (Bsp) and osteocalcin (Oc), for osteoclastic markers, as acid
phosphatase tartrate resistant (Trap) have been evaluated.
2.8. Statistics
Statistical comparisons of gene target expression and histomorphometry were
performed using Two-way ANOVA and Bonferroni post tests in GraphPad Prism 6.0
software. p values <0.05 were considered statistically signiﬁcant.
3. Results
3.1. Bone formation is increased by transplanted hMSC
Histological analyses showed bone tissue and bone marrow
formation at 4 and 8 weeks in all implants consisting of hMSC and
BCP granules (bone incidence 5 out of 5) (Fig. 1A). Conversely, thereTable 1
Sequences of primers used for real-time PCR analysis of mouse genes.
Ofﬁcial Symbol Ofﬁcial full name; Alias
Osteogenic markers Alpl Alkaline phosphatase, li
Bglap Bone gamma-carboxygl
Ibsp Integrin-binding sialo p
Osteoclaetic markers Acp5 Acid phosphatase 5, tar
Ctsk Cathepsin K; Cathk
Reference Alu Alu sequence
Rpl19 Ribosomal protein L19was no bone tissue at 4 weeks and only small quantities of bone
formation without the presence of bone marrow at 8 weeks in the
BCP group without cells (Fig. 1A). Quantiﬁcation by histo-
morphometry revealed a signiﬁcant increase in bone formation
with BCP plus hMSC at 4 and 8 weeks, compared with BCP alone (5
and 10 fold increase respectively, p < 0.001, Fig. 1B). Supporting
these ﬁndings, there was a signiﬁcant up-regulation in the
expression of mouse bone markers, bone sialo protein and osteo-
calcin, in BCP plus hMSC at 1 week compared to BCP alone (Fig. 1C).
In contrast to histological bone detection that increased between 1
and 8 weeks, the gene expression of these bone markers decreased
after 1 week. This apparent discrepancy may be explained by the
loss of efﬁciency in RNA extraction frommineral tissue compared to
soft tissue.
3.2. Transplanted hMSC disappear from implanted site
The presence of hMSC in the implants was evaluated by in situ
hybridization on histological sections and by gene expression of the
speciﬁc human Alu sequence. As illustrated in Fig. 2A, human cells
were detected at 1 and 2weeks within the BCP plus hMSC implants,
while they were not detected at 4 weeks. These results were
corroborated by the relative gene expression of Alu sequence
(Fig. 2B) which detected human cells within BCP plus hMSC im-
plants at 1 and 2 weeks, but with a large decrease of activity be-
tween 1 and 2 weeks (2 fold decrease, p < 0.001, Fig. 2B). As
expected, no human cell transcription was measured in the control
group without human cells. Conﬁrming the in situ hybridization
results, human cell transcription was not detected within the BCP
plus hMSC implants at 4 and 8 weeks.
3.3. Osteoclast activity is enhanced by transplanted hMSC
Distribution of osteoclasts at the implantation site was investi-
gatedby theTRAP staining. Representative stained sections showeda
large production of this resorbing enzyme around the BCP granules
(Fig. 3A). Histomorphometry quantiﬁcation conﬁrmed that hMSC
signiﬁcantly increased osteoclast activity in the implants (more than
a 2 fold increase, p < 0.001, Fig. 3B). There was an increase in the
relative gene expression of the mouse osteoclast markers Cathk and
Trap at 1 and 2weeks in both the BCP group and BCPþ hMSC group;
however there was no difference between the two groups.
3.4. Mobilization of macrophages M0 and M1 to the implant site is
enhanced by transplanted hMSC
The distribution of ﬁrst innate immunological cells, macro-
phagesM0 andM1within the implants was detected in histologicalSense primer antisense primer
ver/bone/kidney; Alp CCGGATCCTGACCAAAAAC
GCCTTACCCTCATGATGTCC
utamic acid-containing protein; Oc AGACTCCGGCGCTACCTT
CAAGCAGGGTTAAGCTCACA
rotein; Bsp CGGCGATAGTTCCGAAGAGGA
CCCCTCAGAATCTTCATTGTTT
trate resistant; Trap CGTCTCTGCACAGATTGCAT
AAGCGCAAACGGTAGTAAGG
GGAGGCGGCTATATGACCA
GGCGTTATACATACAACTTTCATCC
TCTCGATCTCCTGACCTCATGA
TCATGAGGTCAGGAGATCGAGA
TCGTTGCCGGAAAAACAC
AGGTCACCTTCTCAGGCATC
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Fig. 1. Ectopic bone formation increased by BCP granules and hMSC. (A) Representative sections stained with Masson's trichrome of BCP granules (black stars) and hMSC implanted
in paratibial muscle for 1, 2, 4 and 8 weeks. Ectopic bone formation (white stars) was found in the implants at 4 and 8 weeks. Incidence of bone formation in mice is indicated in
white boxes. (B) Percentages of bone formation were evaluated with ImageJ software on the available surface and showed that implantation of human cells increased signiﬁcantly
newly formed bone. (n ¼ 5 mice per group, measurement on 3 levels within each total implant, SED, ***p < 0.001, **p < 0.01) (C) Relative gene expression of Bsp and Oc were
evaluated in BCP and BCP þ hMSC implants. (n ¼ 5 mice per group, SED of triplicate).
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Fig. 2. Disappearence of hMSC after 2 weeks implantation (A) Alu sequence in situ hybridization showed human cells were no longer present within the implants at 4 weeks (scale
bar ¼ 75 mm). (B) Relative gene expression of Alu sequence decreased over time after implantation. (n ¼ 5 mice per group, SED of triplicate ***p < 0.001).
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antibody anti-F4/80, were distributed in ﬁbrous tissue between the
BCP granules, whereas, macrophages M1, labelled by the antibody
anti-iNOS, were primarily located surrounding the BCP biomaterial
(Fig. 4A). Histomorphological quantiﬁcation showed an increase in
the mobilization of macrophages M0 and M1 to the implant site in
the BCP plus hMSC group compared to BCP alone (Fig. 4B). Specif-
ically, macrophages M0 were increased by the presence of hMSC at
2 and 4 weeks and decreased thereafter, while macrophages M1
were signiﬁcantly higher at 4 weeks as a consequence of hMSC.
Presence of macrophages M2 was investigated by immunohis-
tochemistry directed against CD206 and relative gene expression of
CD206, FCGR2, CD163 (data not shown). However, few positive cells
were detected and no difference between the BCP alone group and
the BCP plus hMSC group was found. The presence of pericytes was
also investigated by immunohistochemistry directed against CD146
and relative gene expression of vascular endothelial growth factor
and matrix metallopeptidase 2. The implants were highly vascu-
larised but no difference could be quantiﬁed between the BCP and
BCP þ hMSC groups (data not shown). Moreover, CD146 and in situhybridization of Alu sequence were performed on serial sections of
each implant demonstrating that human cells did not colocolize in
the vessel walls.
3.5. Anti-RANKL treatment induces simultaneous blockage of
osteoclastogenesis and reduced bone formation
Fig. 5 depicts 8week implants in nudemicewith orwithout anti-
RANKL treatment which inhibits osteoclastogenesis. Blockage of
osteoclast activitywas successfulwith a signiﬁcant decrease inTRAP
staining compared to non-treated controls (Fig. 5A and D). Inter-
estingly, inhibition of osteoclastogenesis with anti-RANKL treat-
ment also resulted in a dramatic reduction in bone formation (from
15% to 5%), as highlighted in Fig. 5B and D. Supporting these results,
osteoclastic and osteoblastic gene expression were quantiﬁed and
showed a considerable decrease with mouse anti-RANKL antibody
treatment (Fig. 5E). Thedistribution ofM0macrophageswas studied
by immunohistochemistry directed against CD68 (Fig. 5C). The re-
sults showednodifference in the presence ofmacrophages between
the untreated and mAb anti-RANKL treated groups.
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Fig. 3. Osteoclastogenesis increased by BCP granules and hMSC. (A) Representative sections stained for osteoclast marker tartrate resistant acid phosphatase (TRAP, red) showed an
increase of multinucleacted TRAP positive cells in BCP plus hMSC implants compared with BCP alone implants. (scale bar ¼ 100 mm) (B) Percentages of TRAP staining were evaluated
with ImageJ software on the available surface and showed that implantation of human cells increased signiﬁcantly the number of osteoclast. (n ¼ 5 mice per group, measurement on
3 levels within each total implant, SED, ***p < 0.001) (C) Relative gene expression of Cathk and Trap were evaluated in BCP and BCP þ hMSC implants. (n ¼ 5 mice per group, SED of
triplicate). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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The objective of the present study was to understand the under-
lyingmechanisms of bone formation inducedby thegraftingof hMSC.
To achieve this, micro-porous BCP granules were implanted in the
paratibial muscles of nude mice with or without hMSC and the
chronological events leading to osteoinduction were identiﬁed. Im-
plantation of hMSC considerably enhanced and sped up bone for-
mation. Human cells were not found within the implants at 4 weeks,
proving their role as mediators rather than effectors of bone forma-
tion. The foreign body reaction was studied revealing that hMSC
induced an early mobilization of circulating monocytes to the im-
plantation site as the presence of macrophages and osteoclasts was
signiﬁcantly up-regulated, suggesting their implication in the mech-
anism of bone formation. To more precisely determine the contribu-
tion of osteoclasts to osteogenesis, implantations were repeated in
nude mice treated with mAb anti-RANKL to deplete osteoclast for-
mation and activation. Ablation of osteoclastogenesis signiﬁcantly
impaired bone formation, proving the pivotal role of osteoclast-
mediated bone formation. The implantation of hMSC with BCP ce-
ramics in this study resulted in a 15 fold increase in bone formation
compared toBCPalone. Thisﬁnding is inagreementwithother studies
inbone defects [8] and ectopic sites [7]which show thebone-forming
beneﬁts of implantedMSC.However, the exactmechanisms bywhich
implanted MSC mediate bone induction is unclear. In the past it was
thought that the therapeutic effects of implanted MSC lay in their
ability to differentiate into cells of different lineages, into bone-
forming osteoblasts in the case of bone tissue engineering. However,
in this study the implanted MSC disappeared completely from the
implantation site between 2 and 4weeks and the newly formed bone
tissue was exclusively of host origin, suggesting that the implanted
MSC facilitate but do not participate directly in the bone formation.
Indeed, it has been previously demonstrated that calcium phosphategranules implanted ectopically induced the homing of MSC from the
bonemarrow to the site of CaP particles implantation to form ectopic
bone tissue [11]. Previous studies substantiate the large scale death of
implanted MSC [8,27] which is due to ischaemia [25] and lack of
glucose [26] in the implant microenvironment. It has recently been
shown that the viability of implanted MSC can be maintained in
glucose supplemented implants [26]. Nevertheless, the maintained
viability of implanted MSC was not necessary to initiate bone forma-
tion in this study.
The foreign body reaction against BCP biomaterial and hMSC
was investigated in this study and it was found that BCP granules
initiated a recruitment of cells of the monocyte/macrophage line-
age, which was signiﬁcantly potentiated by the addition of hMSC.
Attraction of macrophages to b-TCP particles was previously
demonstrated in vitro, wherebymacrophagesmigrated towards the
biomaterial by emitting cytoplasmic extensions [28]. Furthermore,
interactions of poly morphonuclear neutrophils with hydroxy-
apatite particles increase levels of pro-inﬂammatory mediators
interleukin-8 (IL-8) and the matrix metallopeptidase 9 [29], a
possible mechanism contributing to the mobilization of monocytes
and macrophages M1 to BCP. The further signiﬁcant increase in
mobilization of cells of the monocyte lineage by the addition of
hMSC in our study, may be explained by the secretion of monocyte
chemo-attractant protein-1 by implanted MSC, which was previ-
ously described in a model of vascular tissue engineering [30].
It has been previously shown that ablated osteoclastogenesis
signiﬁcantly impaired bone formation by calcium phosphate im-
plantations in ectopic sites [19]. However, the present study is the
ﬁrst to investigate hMSC-mediated osteoclast activity in bone for-
mation. Increased bone formation was found when osteoclast and
macrophage M0 and M1 presence was up-regulated at the im-
plantation site by hMSC, and when osteoclastogenesis was abro-
gated a signiﬁcant reduction in bone formation was signiﬁcantly
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Fig. 4. Mobilization of macrophages M0 and M1 enhanced by transplanted hMSC in nude mice. (A) F4/80 and iNOS immunohistological staining of macrophages showed an
increase in mobilization of M0 and M1, respectively, within BCP plus hMSC implants compared to BCP alone (scale bar ¼ 75 mm). (B) Percentages of macrophages M0 and M1 were
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A.-L. Gamblin et al. / Biomaterials 35 (2014) 9660e9667 9665impaired. The precise underlyingmechanisms are unclear, however
several in vitro studies shed light on possible contributing factors
such as the secretion of platelet-derived growth factor by osteo-
clasts which induces the migration of MSC [17] and the production
of oncostatin M by monocyte/macrophages and osteoclasts which
strongly induces the osteogenic differentiation of MSC in vitro
[31,32].
In the present study, in response to the implantation of BCP and
hMSC, numerous macrophages M0 were observed around the parti-
cles and converted into pro-inﬂammatory M1. Co-implantation withhuman cells further enhanced thismechanism. Previous studies have
shown that MSC can regulate the M1/M2 macrophage balance,
favouring a shift towards the M2 anti-inﬂammatory phenotype
[13,15,33]. Thismove towards theM2 phenotype has been implicated
in the resolution of inﬂammation, tissue repair and remodelling in the
heart [34] and kidney [35]. In contrast, the presence of macrophages
M2 (study of 3 gene markers by PCR and 1 speciﬁc protein by
immunohistochemistry), within implants with or without the addi-
tion of human cells was not observed in the current study. Therefore,
macrophage M2 were shown not to be implicated in MSC mediated
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A.-L. Gamblin et al. / Biomaterials 35 (2014) 9660e96679666ectopic bone formation, rathermacrophagesM1 and osteoclastswere
the prominent cells implicated in the ectopic osteogenesis
mechanism.
It would be interesting to study the macrophage role in bone
formation, but independently of the osteoclast one. Alexander et al.
have concluded that osteal macrophages promoted bone healing by
using clodronate treatment and Macrophage Fas-Induced
Apoptosis (MAFIA) transgenic mice model [16]. However, clodro-
nate treatment and conditionally depletion of macrophages in
MAFIA alter the osteoclast differentiation as well as themacrophage one. Furthermore, the MAFIA mouse model is in
immune-competent mice and the bone formation mechanism
should be differently addressed in an immune-deﬁcient model, as
suggested by recent study [36].
In this study, the number of vascular cells within the implants was
quantiﬁed and while the implants were observed to be highly vas-
cularised, no difference between groups was observed. This suggests
that there is no direct implication of vascularised tissue in this
mechanism of ectopic bone formation induced by BCP granules and
hMSC.
A.-L. Gamblin et al. / Biomaterials 35 (2014) 9660e9667 96675. Conclusion
Human MSC signiﬁcantly enhanced ectopic bone formation in
nude mice. They did not participate directly in osteogenesis, rather
they increased the innate immune response and enabled to speed
up the mobilization of monocytes to the implantation site where
they differentiate intomacrophagesM1 and osteoclasts. Ablation of
osteoclastogenesis by anti-RANKL treatment considerably impaired
hMSC-mediated bone formation, highlighting the pivotal role of
osteoclasts in the ectopic bone formation. In nude mice models, an
up-regulation of osteoclasts and macrophages M1 at the implan-
tation site was correlated with increased bone formation due to
hMSC associated to BCP particles.
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